Core Viewpoint - The company, Mike Bio (300463.SZ), has received a medical device registration certificate from the National Medical Products Administration for its pneumonia chlamydia IgG antibody test kit, which is intended for auxiliary diagnosis of pneumonia chlamydia infection [1] Group 1 - The new product is compatible with the company's fully automated chemiluminescence immunoassay analyzers, including the i6000, i3000, i1000, and i800 series [1] - The company has accumulated a total of 140 registered reagent products under the direct chemiluminescence platform to date [1] - The registration of the new product enriches the company's product portfolio, enhancing its overall market competitiveness and positively impacting market expansion and future operations [1]

Core Viewpoint - The company, Maike Bio (300463.SZ), has received a medical device registration certificate from the National Medical Products Administration for its Pneumonia Chlamydia IgG Antibody Test Kit, which enhances its product offerings and market competitiveness [1] Group 1: Product Development - The Pneumonia Chlamydia IgG Antibody Test Kit is a new product developed on the company's direct chemiluminescence platform, aimed at assisting in the diagnosis of Pneumonia Chlamydia infections [1] - The new test kit is compatible with the company's fully automated chemiluminescence immunoassay analyzers, including the i6000, i3000, i1000, and i800 series [1] Group 2: Market Impact - The registration of the new product enriches the company's product portfolio, which now includes a total of 140 registered reagent products under the direct chemiluminescence platform, covering various disease diagnostics such as thyroid function, infectious diseases, cardiac markers, tumor markers, anemia, inflammation, autoimmune diseases, reproductive hormones, and bone metabolism [1] - The introduction of this new product is expected to positively impact the company's market expansion and future operations, enhancing its overall market competitiveness [1]

Core Viewpoint - The company, Maike Bio (300463.SZ), has received a medical device registration certificate from the Sichuan Provincial Drug Administration for its new product, the Glial Fibrillary Acidic Protein Assay Kit, which is intended for auxiliary diagnosis of central nervous system diseases [1] Group 1: Product Registration and Purpose - The Glial Fibrillary Acidic Protein Assay Kit is a new reagent product under the company's direct chemiluminescence platform, used in conjunction with the company's fully automated chemiluminescence immunoassay analyzers (i6000, i3000, i1000, and i800 series) [1] - The company has obtained a total of 138 product registration certificates for reagent products under the direct chemiluminescence platform, covering various disease detections including thyroid function, infectious diseases, myocardial, tumor markers, anemia, inflammation, autoimmune diseases, reproductive hormones, and bone metabolism [1] - The blood cell analyzer quality control products and calibration products are newly added to the company's blood cell platform, ensuring the accuracy of clinical blood cell analysis results [1] Group 2: Registration Details - The blood cell analyzer quality control product has a registration number of 20252400168, valid from September 24, 2025, to September 23, 2030, and is used for quality control of blood cell analysis projects [2] - The Glial Fibrillary Acidic Protein Assay Kit has a registration number of 20252400179, valid from October 17, 2025, to October 16, 2030, for the quantitative measurement of glial fibrillary acidic protein concentration in human serum or plasma [2] - The blood cell analyzer calibration product has a registration number of 20252400180, valid from October 17, 2025, to October 16, 2030, for calibrating parameters such as WBC, RBC, HGB, HCT, and PLT in blood cell analysis [2]